The Price (or Lack) of Global Health

Posted by Ed Schoonveld on Fri, Dec 20, 2019

Governments, private health insurers and employers worldwide are deeply concerned about the increasing cost of healthcare. U.S. healthcare cost as a share of GDP has nearly tripled from 1970 to 2017, resulting in a growing societal burden.


>
Read More

Global Prescription Drug Costs: Why We Need Differential Pricing

Posted by Ed Schoonveld on Wed, Dec 18, 2019

The Trump administration is not the first government to explore the use of international price referencing to force drug prices down. This usually involves the institution of a price ceiling based on an average price for the same drug in a “basket” of other countries. The basket is supposed to consist of countries with similar income levels, but oftentimes that’s not actually the case. That’s just one of the many problems with international price referencing laws.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More

Dangerous, Simple Drug Pricing Solutions

Posted by Ed Schoonveld on Thu, Mar 21, 2019

At a time when drug company CEOs are questioned in Congress and polarized U.S. Democrats and Republicans appear to unite in an intent to act on drug pricing, the industry needs to be very concerned. U.S. politicians and academics are exploring ways to satisfy public thirst for lower drug cost. The biggest danger in today’s Twitter world is the appeal of seemingly simple solutions such as a single-payer system, international price index, ICER and, recently, a three-part pricing model.


>
Read More